Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Lehman who wrote (799)	1/24/1998 12:01:00 PM
From: Harold Engstrom	Read Replies (2) of 1501

HL, here is the part I think refers to VLA-4. VLA-4 is part of their small molecule program and during the annual meeting Dr. Davies mentioned (I think I remember this) that this molecule seemed small enough to be taken orally. Also, they said VLA-4 will be tested on MS. But anyway, here is the part of the transcript that I think may apply: ROBERT LEBOYER: I have a quick question on the additional AVONEXr trials that you have running. You seem to have a whole variety of trials, but the one thing that I haven't heard is anything on oral delivery using technology that MSV or Alkermes has. Do you plan such things or if not, why not? JIM TOBIN: We have no plans, at this point, to pursue delivery of proteins. We have other molecules that can be delivered orally that hold out the promise of being effective in MS, and it's our feeling that we're better off moving to the next generation of product for an oral; rather than trying to beat our heads against the oral delivery of this protein.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next